Gediz Fusun, Ugur Mehmet Can, Turkmen Meltem, Kobak Senol
Department of Hematology, University of Health Sciences, İzmir Bozyaka Training and Research Hospital, Turkey.
Department of Dermatology,, University of Health Sciences, İzmir Bozyaka Training and Research Hospital, Turkey.
Reumatologia. 2021;59(1):58-61. doi: 10.5114/reum.2021.102618. Epub 2021 Feb 28.
Psoriatic arthritis (PsA) is a chronic inflammatory disease characterized by skin and joint involvement. The disease may present with various joint pattern involvement, which sometimes may lead to joint destruction and deformity. Early diagnosis and treatment with disease-modifying anti-rheumatic drugs may prevent joint deformity. Recently there are many new treatment options including biologic drugs. Ustekinumab, an interleukin 12/23 inhibitor, has proven efficacy in the treatment of psoriatic arthritis. Like other biologic drugs (anti-TNF-α), there are contradictory data about the safety of ustekinumab and possible relationship with cancer development. Herein we report the development of chronic lymphocytic leukemia in a patient with PsA treated with ustekinumab.
银屑病关节炎（PsA）是一种以皮肤和关节受累为特征的慢性炎症性疾病。该疾病可能表现为多种关节受累模式，有时可能导致关节破坏和畸形。早期诊断并用改善病情的抗风湿药物治疗可预防关节畸形。最近有许多新的治疗选择，包括生物药物。乌司奴单抗，一种白细胞介素12/23抑制剂，已被证明在治疗银屑病关节炎方面有效。与其他生物药物（抗TNF-α）一样，关于乌司奴单抗的安全性以及与癌症发生的可能关系存在相互矛盾的数据。在此，我们报告一例接受乌司奴单抗治疗的PsA患者发生慢性淋巴细胞白血病的情况。
